---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-042005"
form_type: "8-K"
ticker: "SERA"
cik: "0001534969"
company_name: "SERA PROGNOSTICS, INC."
filed_at: "2025-03-19T23:59:59+00:00"
generated_at: "2026-05-24T11:42:47.359981+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sera Prognostics Q4 revenue $24k; PRIME study meets primary endpoints; raised $57.5M

## Summary
- Q4 2024 revenue $24,000; net loss $8.6M vs $7.9M prior year.
- PRIME study: 25% reduction in neonatal morbidity/mortality index and 18% reduction in length of stay in modified ITT.
- Full year 2024 revenue $77,000; net loss $32.9M vs $36.2M in 2023.
- Raised $57.5M in Feb 2025 public offering; cash runway extended through 2028.
- R&D expenses $3.1M in Q4, down 19% YoY.

## SEC filing metadata
- accession: 0000950170-25-042005
- form_type: 8-K
- ticker: SERA
- cik: 0001534969
- company_name: SERA PROGNOSTICS, INC.
- filed_at: 2025-03-19T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534969/000095017025042005/0000950170-25-042005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534969/000095017025042005/sera-20250319.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-042005
- JSON: https://secwatch.observer/filing/0000950170-25-042005.json
- Plain text: https://secwatch.observer/filing/0000950170-25-042005.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.